Clinical trial
Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation (AF) Versus Long Term Warfarin Therapy
NCT01182441 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation (AF) Versus Long Term Warfarin Therapy
- Lead sponsor
- Boston Scientific Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- November 30, 2017
- Enrollment
- 407 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.